Money Is Rotating — And This Biotech Medical Play Is Hard to Ignore
This small-cap stock, which has nothing to do with AI disruption, is exactly the kind I look for in a rotational market.
You're reading 0 of 1 free page.
Register to read more or Unlock Pro — 50% Off Ends Soon
A huge Nvidia (NVDA) earnings report isn't good enough to save the market from AI chaos. Nvidia is down about 3.7% on what analysts are hailing as one of the best quarters ever and it is dragging down the Nasdaq 100 (QQQ) , SPDR Select Technology ETF (XLK) , the Magnificent Seven (MAGS) , and semiconductors (SMH) .
The good news is that breadth is about 55% positive, which is a sign that there is rotational action out of AI-related names and not just a broad market selloff. There are pockets of positive action but no real themes. There is a bunch of random stocks that are doing OK as traders look for safe harbors.
Despite the rotational action, weakness in technology and AI does hurt sentiment and that causes higher levels of illiquidity. When that happens many smaller stocks lose bids and drift lower even though there isn't any change in fundamentals.
This is a very tough market but my game plan right now is to try to find stocks with good fundamentals that are holding up and offering lower risk entry points. One place to find those situations is in small-cap earnings reports.
ADMA Biologics: A Plasma Company With a Powerful Edge
One small-cap earnings report on Wednesday night that caught my eye is ADMA Biologics (ADMA) , which I have followed for a long time. The stock has had its ups and downs but the niche is compelling and after this earnings report the valuation is hard to ignore.
ADMA is not a typical biotech story. There are no clinical trial binary events to navigate and no FDA approval to wait for. This is a vertically integrated plasma company that collects human blood plasma, processes it at its FDA-licensed facility in Boca Raton, and turns it into injectable immunoglobulin products that treat patients with compromised immune systems. The business is real and growing fast and the stock is cheap.
The star of the show is ASCENIV, which is 71% of total revenue and the only product of its kind on the market. ADMA manufactures it by blending plasma from donors with naturally elevated respiratory virus antibodies with standard plasma. The result is a product that delivers 1.4 to 1.9 times the antibody levels of competing immunoglobulins across nine respiratory pathogens. It commands 5.5 to 6 times the price of standard IG, is patent-protected through 2035, and ADMA still holds just 3% of a U.S. immunoglobulin market that exceeded $13 billion in 2024. The runway here is enormous.
Items Shaping Our Investment Thesis
Two developments are reshaping the financial model. First, the FDA approved a yield-enhancement process last April that squeezes roughly 20% more finished product from the same volume of starting plasma. ADMA was the first U.S. producer to achieve that milestone.
Since plasma is the largest input cost and cannot be synthesized, the margin leverage is significant. The company exited Q4 2025 at a 63.8% gross margin, nearly 1,000 basis points above the prior year. 2026 will be the first full year of yield-enhanced production and the margin expansion story is just getting started.
Second, a new distribution agreement with McKesson Specialty, signed in Q4, opens access to sites of care that ADMA's existing network couldn't reach. Management expects the ramp to materialize primarily in the back half of 2026. That is a meaningful growth catalyst that isn't fully priced in yet.
The numbers back up the thesis. Q4 revenue came in at $139.2 million, up 18% year over year. Full-year 2025 revenue was $510.2 million, a 20% increase. ASCENIV alone delivered $363 million in full year sales, up 51%. The company beat Wall Street's EPS estimate of $0.20 with $0.215 and Q4 adjusted EBITDA surged 52%.
For 2026 management is guiding revenue above $635 million, adjusted net income above $255 million, and adjusted EBITDA exceeding $360 million. The longer-range target is north of $1.1 billion in revenue by 2029.
One item worth watching. Accounts receivable ballooned to $158.4 million, growing far faster than revenue. Management says that this normalizes as McKesson ramps and distribution diversifies. That explanation makes sense, but it bears monitoring.
Valuation
On valuation, the stock sits around $15.70, down roughly 14% year to date despite strong execution. Against Wall Street's $0.90 consensus 2026 EPS, the stock trades at about 17.4 times forward earnings. Against management's own adjusted guidance, which implies north of $1.05 per share, the multiple drops to roughly 15 times. The PEG ratio ranges from 0.18 to 0.35, well below the 1.0 threshold that typically signals fair value for a growth company.
Three covering analysts rate the stock a Strong Buy with an average target around $26, implying roughly 65% upside from current levels. No post-earnings analyst notes have dropped yet but given the beat-and-raise quarter upward estimate revisions would not be a surprise.
Bottom Line
This is exactly the kind of stock I look for in a rotational market. It has nothing to do with AI disruption; it has real earnings, expanding margins, a defensible moat through 2035, and a valuation that doesn't reflect the growth trajectory.
The stock is thin and under the radar, and there may not be much immediate interest, but that is why I want to work into it incrementally as it develops. Management still has to execute, but if it does, the stock has substantial upside.
At the time of publication, Rev Shark was long NVDA and ADMA.
